Search: onr:"swepub:oai:DiVA.org:uu-440998" > Addition of lenalid...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 08033naa a2200889 4500 | |
001 | oai:DiVA.org:uu-440998 | |
003 | SwePub | |
008 | 210426s2021 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4409982 URI |
024 | 7 | a https://doi.org/10.1182/bloodadvances.20200038552 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Löwenberg, Bobu Erasmus Univ Med Ctr MC, Rotterdam, Netherlands.;Erasmus MC Canc Inst, Rotterdam, Netherlands.4 aut |
245 | 1 0 | a Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML :b the HOVON-SAKK-132 trial |
264 | c 2021-02-22 | |
264 | 1 | b American Society of Hematology,c 2021 |
338 | a print2 rdacarrier | |
520 | a Lenalidomide, an antineoplastic and immunomodulatory drug, has therapeutic activity in acute myeloid leukemia (AML), but definitive studies about its therapeutic utility have been lacking. In a phase 3 study, we compared 2 induction regimens in newly diagnosed patients age 18 to 65 years with AML: idarubicine-cytarabine (cycle 1) and daunorubicin and intermediate-dose cytarabine (cycle 2) without or with lenalidomide (15 mg orally on days 1-21). One final consolidation cycle of chemotherapy or autologous stem cell transplantation (auto-SCT) or allogeneic SCT (allo-SCT) was provided according to a prognostic risk and minimal residual disease (MRD)-adapted approach. Event-free survival (EFS; primary end point) and other clinical end points were assessed. A second random assignment in patients in complete response or in complete response with incomplete hematologic recovery after cycle 3 or auto-SCT involved 6 cycles of maintenance with lenalidomide (10 mg on days 1-21) or observation. In all, 392 patients were randomly assigned to the control group, and 388 patients were randomly assigned to lenalidomide induction. At a median follow-up of 41 months, the study revealed no differences in outcome between the treatments (EFS, 44% +/- 2% standard error and overall survival, 54% = 2% at 4 years for both arms) although in an exploratory post hoc analysis, a lenalidomide benefit was suggested in SRSF2-mutant AML. In relation to the previous Dutch-Belgian Hemato-Oncology Cooperative Group and Swiss Group for Clinical Cancer Research (HOVON-SAKK) studies that used a similar 3-cycle regimen but did not pursue an MRD-guided approach, these survival estimates compare markedly more favorably. MRD status after cycle 2 lost prognostic value in intermediate-risk AML in the risk-adjusted treatment context. Maintenance with lenalidomide showed no apparent effect on relapse probability in 88 patients randomly assigned for this part of the study. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
700 | 1 | a Pabst, Thomasu Inselspital Bern, Bern, Switzerland.4 aut |
700 | 1 | a Maertens, Johanu Univ Hosp Gasthuisberg, Leuven, Belgium.4 aut |
700 | 1 | a Gradowska, Patrycjau Erasmus MC Canc Inst, Dutch Belgian Hematooncol Cooperat Grp Data Ctr, Rotterdam, Netherlands.4 aut |
700 | 1 | a Biemond, Bart J.u Amsterdam Univ Med Ctr, Amsterdam, Netherlands.4 aut |
700 | 1 | a Spertini, Olivieru Univ Lausanne UNIL, Lausanne Univ Hosp, Ctr Hosp Univ Vaudois, Lausanne, Switzerland.4 aut |
700 | 1 | a Vellenga, Edou Univ Groningen, Univ Med Ctr, Groningen, Netherlands.4 aut |
700 | 1 | a Griskevicius, Laimonasu Vilnius Univ Hosp, Santaros Klin, Vilnius, Lithuania.;Vilnius Univ, Vilnius, Lithuania.4 aut |
700 | 1 | a Tick, Lidwine W.u Maxima Med Ctr, Eindhoven, Netherlands.4 aut |
700 | 1 | a Jongen-Lavrencic, Mojcau Erasmus Univ Med Ctr MC, Rotterdam, Netherlands.;Erasmus MC Canc Inst, Rotterdam, Netherlands.4 aut |
700 | 1 | a Kooy, Marinus van Marwijku Isala Hosp, Zwolle, Netherlands.4 aut |
700 | 1 | a Vekemans, Marie-Christianeu Univ Hosp St Luc, Brussels, Belgium.4 aut |
700 | 1 | a van der Velden, Walter J. F. M.u Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands.4 aut |
700 | 1 | a Beverloo, Bernau Erasmus Univ MC, Dept Clin Genet, Rotterdam, Netherlands.4 aut |
700 | 1 | a Michaux, Lucienneu Katholieke Univ Leuven, Ctr Human Genet, Leuven, Belgium.;Univ Hosp Leuven, Leuven, Belgium.4 aut |
700 | 1 | a Graux, Carlosu Univ Catholique Louvain Namur Godinne, Yvoir, Belgium.4 aut |
700 | 1 | a Deeren, Driesu AZ Delta, Roeselare, Belgium.4 aut |
700 | 1 | a de Weerdt, Okkeu St Antonius Hosp, Nieuwegein, Netherlands.4 aut |
700 | 1 | a van Esser, Joost W. J.u Amphia Hosp, Breda, Netherlands.4 aut |
700 | 1 | a Bargetzi, Mariou Kantonsspittal, Aarau, Switzerland.4 aut |
700 | 1 | a Klein, Saskia K.u Meander Med Ctr, Amersfoort, Netherlands.4 aut |
700 | 1 | a Gadisseur, Alainu Univ Hosp Antwerpen, Edegem, Belgium.4 aut |
700 | 1 | a Westerweel, Peter E.u Albert Schweitzer Hosp, Dordrecht, Netherlands.4 aut |
700 | 1 | a Veelken, Hendriku Univ Med Ctr, Leiden, Netherlands.4 aut |
700 | 1 | a Gregor, Michaelu Luzerner Kantonsspittal, Luzern, Switzerland.4 aut |
700 | 1 | a Silzle, Tobiasu Kantonsspittal, St Gallen, Switzerland.4 aut |
700 | 1 | a Van Lammeren-Venema, Danielleu Haga Hosp, The Hague, Netherlands.4 aut |
700 | 1 | a Moors, Ineu Univ Hosp, Ghent, Belgium.4 aut |
700 | 1 | a Breems, Dimitri A.u Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium.4 aut |
700 | 1 | a Hoogendoorn, Melsu Med Spectrum Leeuwarden, Leeuwarden, Netherlands.4 aut |
700 | 1 | a Legdeur, Marie-Cecile J. C.u Med Spectrum Twente, Enschede, Netherlands.4 aut |
700 | 1 | a Fischer, Thomasu Otto von Guericke Univ Hosp Magdeburg, Magdeburg, Germany.4 aut |
700 | 1 | a Kuball, Juergenu Univ Med Ctr Utrecht, Utrecht, Netherlands.4 aut |
700 | 1 | a Cornelissen, Janu Erasmus Univ Med Ctr MC, Rotterdam, Netherlands.;Erasmus MC Canc Inst, Rotterdam, Netherlands.4 aut |
700 | 1 | a Porkka, Kimmou Helsinki Univ Hosp Canc Ctr, Helsinki, Finland.4 aut |
700 | 1 | a Juliusson, Gunnaru Skanes Univ Hosp, Lund, Sweden.4 aut |
700 | 1 | a Meyer, Peteru Stavanger Univ Hosp Rogaland, Stavanger, Norway.4 aut |
700 | 1 | a Höglund, Martinu Uppsala universitet,Hematologi4 aut0 (Swepub:uu)martinhl |
700 | 1 | a Gjertsen, Bjorn T.u Haukeland Hosp, Bergen, Norway.4 aut |
700 | 1 | a Janssen, Jeroen J. W. M.u Amsterdam Vrije Univ, Med Ctr, Amsterdam, Netherlands.4 aut |
700 | 1 | a Huls, Gerwinu Univ Groningen, Univ Med Ctr, Groningen, Netherlands.4 aut |
700 | 1 | a Passweg, Jakobu Univ Hosp, Basel, Switzerland.4 aut |
700 | 1 | a Cloos, Jacquelineu Amsterdam Vrije Univ, Med Ctr, Amsterdam, Netherlands.4 aut |
700 | 1 | a Valk, Peter J. M.u Erasmus Univ Med Ctr MC, Rotterdam, Netherlands.;Erasmus MC Canc Inst, Rotterdam, Netherlands.4 aut |
700 | 1 | a van Elssen, Catharina H. M. J.u Univ Med Ctr, Maastricht, Netherlands.4 aut |
700 | 1 | a Manz, Markus G.u Univ Hosp, Zurich, Switzerland.4 aut |
700 | 1 | a Floisand, Yngvaru Oslo Univ Hosp, Oslo, Norway.4 aut |
700 | 1 | a Ossenkoppele, Gert J.u Amsterdam Vrije Univ, Med Ctr, Amsterdam, Netherlands.4 aut |
710 | 2 | a Erasmus Univ Med Ctr MC, Rotterdam, Netherlands.;Erasmus MC Canc Inst, Rotterdam, Netherlands.b Inselspital Bern, Bern, Switzerland.4 org |
773 | 0 | t Blood Advancesd : American Society of Hematologyg 5:4, s. 1110-1121q 5:4<1110-1121x 2473-9529x 2473-9537 |
856 | 4 | u https://ashpublications.org/bloodadvances/article-pdf/5/4/1110/1800710/advancesadv2020003855.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-440998 |
856 | 4 8 | u https://doi.org/10.1182/bloodadvances.2020003855 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.